Recent Advances in Engineering Carriers for siRNA Delivery
© 2024 Wiley‐VCH GmbH..
RNA interference (RNAi) technology has been a promising treatment strategy for combating intractable diseases. However, the applications of RNAi in clinical are hampered by extracellular and intracellular barriers. To overcome these barriers, various siRNA delivery systems have been developed in the past two decades. The first approved RNAi therapeutic, Patisiran (ONPATTRO) using lipids as the carrier, for the treatment of amyloidosis is one of the most important milestones. This has greatly encouraged researchers to work on creating new functional siRNA carriers. In this review, the recent advances in siRNA carriers consisting of lipids, polymers, and polymer-modified inorganic particles for cancer therapy are summarized. Representative examples are presented to show the structural design of the carriers in order to overcome the delivery hurdles associated with RNAi therapies. Finally, the existing challenges and future perspective for developing RNAi as a clinical modality will be discussed and proposed. It is believed that the addressed contributions in this review will promote the development of siRNA delivery systems for future clinical applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Macromolecular bioscience - 24(2024), 4 vom: 15. Apr., Seite e2300362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Chengbin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cationic natural polymers |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mabi.202300362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36640945X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36640945X | ||
| 003 | DE-627 | ||
| 005 | 20240416232421.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mabi.202300362 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM36640945X | ||
| 035 | |a (NLM)38150293 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Chengbin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Advances in Engineering Carriers for siRNA Delivery |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley‐VCH GmbH. | ||
| 520 | |a RNA interference (RNAi) technology has been a promising treatment strategy for combating intractable diseases. However, the applications of RNAi in clinical are hampered by extracellular and intracellular barriers. To overcome these barriers, various siRNA delivery systems have been developed in the past two decades. The first approved RNAi therapeutic, Patisiran (ONPATTRO) using lipids as the carrier, for the treatment of amyloidosis is one of the most important milestones. This has greatly encouraged researchers to work on creating new functional siRNA carriers. In this review, the recent advances in siRNA carriers consisting of lipids, polymers, and polymer-modified inorganic particles for cancer therapy are summarized. Representative examples are presented to show the structural design of the carriers in order to overcome the delivery hurdles associated with RNAi therapies. Finally, the existing challenges and future perspective for developing RNAi as a clinical modality will be discussed and proposed. It is believed that the addressed contributions in this review will promote the development of siRNA delivery systems for future clinical applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cationic natural polymers | |
| 650 | 4 | |a cationic synthetic polymers | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a lipids | |
| 650 | 4 | |a polymer‐modified inorganic nanoparticles | |
| 650 | 4 | |a siRNA delivery | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Lin, Zheng-Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xinmeng |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zhourui |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Gaixia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yu-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Tzu-Hsien |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Pei-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Law, Wing-Cheung |e verfasserin |4 aut | |
| 700 | 1 | |a Yong, Ken-Tye |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Chih-Kuang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Macromolecular bioscience |d 2004 |g 24(2024), 4 vom: 15. Apr., Seite e2300362 |w (DE-627)NLM151409706 |x 1616-5195 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:e2300362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mabi.202300362 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 4 |b 15 |c 04 |h e2300362 | ||